LFCR Overview

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization that provides services in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes, vials and cartridges. It manufactures pharmaceutical-grade, non-animal-sourced hyaluronic acid (HA) using fermentation-based HA process. It manufactures HA in bulk form and for use in formulated and filled syringes and vials for our customers’ injectable products used in treating medical conditions and procedures, including ophthalmic and orthopedic applications. Its product development service capabilities include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation and production of materials for clinical studies. It also operates semi-automated restricted access barrier systems (RABS) and fully automated aseptic filling lines with isolators.

Wall Street analysts forecast LFCR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFCR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lifecore Biomedical Inc revenue for the last quarter amounts to 31.11M USD, increased 25.92

Lifecore Biomedical Inc. EPS for the last quarter amounts to -0.29 USD, decreased -45.28

Lifecore Biomedical Inc (LFCR) has 382 emplpoyees as of March 31 2026.

Today LFCR has the market capitalization of 142.04M USD.